Znomics Inc. (ZNOM) is a biotechnology company that develops new pharmaceutical products for the treatment of human diseases. They approach product development with a two-pronged attack: commercial and academics. Commercially, the company is constantly seeking the development of proprietary drugs both autonomously and collaboratively with partner companies. Academically, Znomics provides labor and materials to, and develops collaborative relationships with, researchers engaged in advancing biological science, thereby enhancing their intellectual property and drug development capabilities.
Although Znomics is still a developmental stage biotech company, they have many unique qualities which offer strong comparative advantages to many of their revenue generating counterparts. The company employs a relatively efficient and cost-effective system for drug development that uses zebrafish. These creatures share 80-90% of the genes found in humans but contain many unique attributes that create the potential for faster, more effective drug discovery. These unique characteristics are why Znomics is one of over 500 laboratories worldwide that now conducts research using the zebrafish.
The primary intent of Znomic’s drug discovery efforts are to make the world a better place through the creation of life saving drugs, but they also aim to sell their genetically mutated zebrafish to other laboratories and research universities for profit. Company management intends to initiate their first three development programs before the completion of 2008, and to discover three lead developmental compounds within the next three years. It is hard to rate an early stage biotechnology company before the development of drugs or the recognition of significant revenue, but Znomics already has the leadership and technology that is required for success.
Let us hear your thoughts: Znomics Inc. Message Board